What makes an iGEM winner?

Covering iGEM is hard: choosing presentations based on what sounds cool won?t get you very far, because almost everything sounds cool. Who would say no to a microbial mass production system for blood (Berkeley) or RNAi components strung together to create a way to cure cancer (Princeton)? But with most of the projects so conceptually ambitious, one of the judges told me, sifting through them really requires squaring what was originally planned with what got accomplished. Ten or so groups have

Written byAlla Katsnelson
| 1 min read

Register for free to listen to this article
Listen with Speechify
0:00
1:00
Share
Covering iGEM is hard: choosing presentations based on what sounds cool won?t get you very far, because almost everything sounds cool. Who would say no to a microbial mass production system for blood (Berkeley) or RNAi components strung together to create a way to cure cancer (Princeton)? But with most of the projects so conceptually ambitious, one of the judges told me, sifting through them really requires squaring what was originally planned with what got accomplished. Ten or so groups have made chemical sensors, for example, but there's a huge range in how well they built their systems, said James Brown, who is mentoring the Cambridge University group this year. He pointed me to MIT's mercury sensor, which also acts as a filter that can clean contaminated water. They used induction with AHL, a quorum-sensing molecule often used in biosensors, to activate two constructs, one of which reports mercury while the other binds it. Drew Endy of MIT, who is in charge of the judging with Chris Voigt from UCSF, told me that an idea that makes compelling use of biotechnology is worth a lot, but of course, that?s coupled with what a team is able to deliver. Another criteria of judges is what a team gives back to the community in biological parts that can be added to the Registry (which I described in my linkurl:post;http://www.the-scientist.com/blog/display/53822/ last night), but there's a huge range in whether groups end up contributing.
Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here

Meet the Author

Share
Image of a man in a laboratory looking frustrated with his failed experiment.
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies